Market Cap 22.98M
Revenue (ttm) 490,000.00
Net Income (ttm) -51.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,493.88%
Debt to Equity Ratio 0.00
Volume 292,700
Avg Vol 837,918
Day's Range N/A - N/A
Shares Out 39.62M
Stochastic %K 20%
Beta 0.31
Analysts Hold
Price Target $0.97

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 577 3600
Address:
343 Allerton Avenue, South San Francisco, United States
ThaDankles
ThaDankles Jun. 4 at 9:13 PM
0 · Reply
invisiblehand21
invisiblehand21 Jun. 4 at 8:43 PM
$VTGN wen results
1 · Reply
smooth2222
smooth2222 Jun. 4 at 2:45 PM
$VTGN Down on low volume, should bounce back nicely, imo
0 · Reply
Chessdoc
Chessdoc Jun. 4 at 1:49 PM
$VTGN Buying calls for July
0 · Reply
pops132005
pops132005 Jun. 4 at 1:41 PM
$VTGN anyone know how to listen to the Jefferies conference?
2 · Reply
Chessdoc
Chessdoc Jun. 4 at 11:57 AM
$VTGN When are results of Palisade 4 expected please?
1 · Reply
TheDragonsClaw
TheDragonsClaw Jun. 4 at 9:25 AM
0 · Reply
MaskMaker
MaskMaker Jun. 4 at 5:49 AM
0 · Reply
SnoopDawg
SnoopDawg Jun. 4 at 12:03 AM
$VTGN ​Here is how the baseline approach differs between palisades 3 and 4: ​The Baseline Statistical Shift ​PALISADE-3 Baseline Approach: The trial measured the change in a patient's self-reported anxiety using the Subjective Units of Distress Scale (SUDS) during a simulated public speaking challenge. However, it lacked a refined, tight adjustment for the exact level of distress a patient felt immediately before the investigational product was administered. This left the trial highly vulnerable to "measurement noise" and a massive placebo response (where placebo patients showed nearly identical SUDS point reductions to the fasedienol group). ​PALISADE-4 Refined Baseline Approach: In May 2026, Vistagen updated the PALISADE-4 SAP to incorporate each participant's precise distress level immediately prior to dosing (pre-IP SUDS) as a formal baseline covariate in the primary efficacy analysis. ​This locks in the pre-dose SUDS score as a baseline covariate to reduce noise.
1 · Reply
MaskMaker
MaskMaker Jun. 3 at 8:33 PM
1 · Reply
Latest News on VTGN
Vistagen appoints Angelov as Chief Medical Officer

2026-05-19T12:37:06.000Z - 16 days ago

Vistagen appoints Angelov as Chief Medical Officer


Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 17, 2026, 9:00 AM EDT - 2 months ago

Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum


Vistagen to Participate in Upcoming Investor Conferences

Mar 3, 2026, 8:30 AM EST - 3 months ago

Vistagen to Participate in Upcoming Investor Conferences


Vistagen Therapeutics Earnings Call Transcript: Q3 2026

Feb 12, 2026, 5:00 PM EST - 4 months ago

Vistagen Therapeutics Earnings Call Transcript: Q3 2026


Vistagen Therapeutics Quarterly report: Q3 2026

Feb 12, 2026, 5:00 PM EST - 4 months ago

Vistagen Therapeutics Quarterly report: Q3 2026


Vistagen Therapeutics Earnings release: Q3 2026

Feb 12, 2026, 5:00 PM EST - 4 months ago

Vistagen Therapeutics Earnings release: Q3 2026


Vistagen downgraded to Hold from Buy at Jefferies

2025-12-17T19:25:24.000Z - 6 months ago

Vistagen downgraded to Hold from Buy at Jefferies


Vistagen downgraded to Hold from Buy at Maxim

2025-12-17T17:20:14.000Z - 6 months ago

Vistagen downgraded to Hold from Buy at Maxim


Vistagen downgraded to Hold from Buy at Stifel

2025-12-17T15:45:17.000Z - 6 months ago

Vistagen downgraded to Hold from Buy at Stifel


Vistagen downgraded to Neutral from Buy at Lucid Capital

2025-12-17T14:40:46.000Z - 6 months ago

Vistagen downgraded to Neutral from Buy at Lucid Capital


Vistagen SAD study did not achieve primary endpoint

2025-12-17T14:05:58.000Z - 6 months ago

Vistagen SAD study did not achieve primary endpoint


VistaGen Therapeutics trading resumes

2025-12-17T13:55:10.000Z - 6 months ago

VistaGen Therapeutics trading resumes


VistaGen Therapeutics trading halted, news pending

2025-12-17T13:25:17.000Z - 6 months ago

VistaGen Therapeutics trading halted, news pending


Vistagen names Nick Tressler CFO

2025-12-01T14:00:20.000Z - 6 months ago

Vistagen names Nick Tressler CFO


Vistagen Appoints Nick Tressler as Chief Financial Officer

Dec 1, 2025, 8:30 AM EST - 6 months ago

Vistagen Appoints Nick Tressler as Chief Financial Officer


Vistagen Therapeutics Earnings Call Transcript: Q2 2026

Nov 13, 2025, 5:00 PM EST - 7 months ago

Vistagen Therapeutics Earnings Call Transcript: Q2 2026


Vistagen Therapeutics Quarterly report: Q2 2026

Nov 13, 2025, 5:00 PM EST - 7 months ago

Vistagen Therapeutics Quarterly report: Q2 2026


Vistagen Therapeutics Earnings release: Q2 2026

Nov 13, 2025, 5:00 PM EST - 7 months ago

Vistagen Therapeutics Earnings release: Q2 2026


Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 5, 2025, 8:30 AM EST - 7 months ago

Vistagen to Participate in Stifel Healthcare Conference 2025


Vistagen Appoints Paul Edick to its Board of Directors

Oct 29, 2025, 8:30 AM EDT - 7 months ago

Vistagen Appoints Paul Edick to its Board of Directors


Vistagen to Present at The Menopause Society 2025 Annual Meeting

Oct 16, 2025, 8:30 AM EDT - 8 months ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting


Vistagen Therapeutics Transcript: AGM 2025

Sep 9, 2025, 12:00 PM EDT - 9 months ago

Vistagen Therapeutics Transcript: AGM 2025


Vistagen Therapeutics Earnings Call Transcript: Q1 2026

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Vistagen Therapeutics Earnings Call Transcript: Q1 2026


Vistagen Therapeutics Quarterly report: Q1 2026

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Vistagen Therapeutics Quarterly report: Q1 2026


Vistagen Therapeutics Earnings release: Q1 2026

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Vistagen Therapeutics Earnings release: Q1 2026


Vistagen Therapeutics Proxy statement: Proxy Filing

Jul 28, 2025, 8:00 AM EDT - 11 months ago

Vistagen Therapeutics Proxy statement: Proxy Filing


Vistagen Therapeutics Proxy statement: Proxy Filing

Jul 28, 2025, 8:00 AM EDT - 11 months ago

Vistagen Therapeutics Proxy statement: Proxy Filing


Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 11 months ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference


Vistagen Therapeutics Earnings Call Transcript: Q4 2025

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings Call Transcript: Q4 2025


Vistagen Therapeutics Earnings release: Q4 2025

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings release: Q4 2025


Vistagen Therapeutics Annual report: Q4 2025

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Annual report: Q4 2025


Vistagen Therapeutics Transcript: Stifel 2025 Virtual CNS Forum

Mar 18, 2025, 12:00 PM EDT - 1 year ago

Vistagen Therapeutics Transcript: Stifel 2025 Virtual CNS Forum


Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Mar 4, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum


Vistagen Therapeutics Earnings Call Transcript: Q3 2025

Feb 13, 2025, 5:00 PM EST - 1 year ago

Vistagen Therapeutics Earnings Call Transcript: Q3 2025


Vistagen Therapeutics Quarterly report: Q3 2025

Feb 13, 2025, 5:00 PM EST - 1 year ago

Vistagen Therapeutics Quarterly report: Q3 2025


Vistagen Therapeutics Earnings release: Q3 2025

Feb 13, 2025, 5:00 PM EST - 1 year ago

Vistagen Therapeutics Earnings release: Q3 2025


ThaDankles
ThaDankles Jun. 4 at 9:13 PM
0 · Reply
invisiblehand21
invisiblehand21 Jun. 4 at 8:43 PM
$VTGN wen results
1 · Reply
smooth2222
smooth2222 Jun. 4 at 2:45 PM
$VTGN Down on low volume, should bounce back nicely, imo
0 · Reply
Chessdoc
Chessdoc Jun. 4 at 1:49 PM
$VTGN Buying calls for July
0 · Reply
pops132005
pops132005 Jun. 4 at 1:41 PM
$VTGN anyone know how to listen to the Jefferies conference?
2 · Reply
Chessdoc
Chessdoc Jun. 4 at 11:57 AM
$VTGN When are results of Palisade 4 expected please?
1 · Reply
TheDragonsClaw
TheDragonsClaw Jun. 4 at 9:25 AM
0 · Reply
MaskMaker
MaskMaker Jun. 4 at 5:49 AM
0 · Reply
SnoopDawg
SnoopDawg Jun. 4 at 12:03 AM
$VTGN ​Here is how the baseline approach differs between palisades 3 and 4: ​The Baseline Statistical Shift ​PALISADE-3 Baseline Approach: The trial measured the change in a patient's self-reported anxiety using the Subjective Units of Distress Scale (SUDS) during a simulated public speaking challenge. However, it lacked a refined, tight adjustment for the exact level of distress a patient felt immediately before the investigational product was administered. This left the trial highly vulnerable to "measurement noise" and a massive placebo response (where placebo patients showed nearly identical SUDS point reductions to the fasedienol group). ​PALISADE-4 Refined Baseline Approach: In May 2026, Vistagen updated the PALISADE-4 SAP to incorporate each participant's precise distress level immediately prior to dosing (pre-IP SUDS) as a formal baseline covariate in the primary efficacy analysis. ​This locks in the pre-dose SUDS score as a baseline covariate to reduce noise.
1 · Reply
MaskMaker
MaskMaker Jun. 3 at 8:33 PM
1 · Reply
TheDragonsClaw
TheDragonsClaw Jun. 3 at 7:36 PM
1 · Reply
marketCaptain
marketCaptain Jun. 3 at 6:13 PM
$VTGN Zero chance smt has been unblinded/leak. Just ppl derisking, same thing the weeks before pal3, they maybe hoped for a runup before readout.
0 · Reply
smooth2222
smooth2222 Jun. 3 at 5:04 PM
$VTGN Down on low volume
0 · Reply
jmuu001
jmuu001 Jun. 3 at 4:57 PM
$VTGN Hasn't even been 4 weeks since last patient. Think it was 6 weeks for Palisade-3. Trial is probably still blinded. Why would they unblind with Singh meeting investors at Jefferies conference this week.
0 · Reply
ThaDankles
ThaDankles Jun. 3 at 4:48 PM
$VTGN any day now
0 · Reply
thedigitalnobody
thedigitalnobody Jun. 3 at 2:51 PM
$VTGN I'm out. This is nothing but an Indian scam.
1 · Reply
marketCaptain
marketCaptain Jun. 3 at 12:14 PM
$VTGN 61 now, damn lots of holders got rugged yesterday
0 · Reply
MakesHerSquirt
MakesHerSquirt Jun. 2 at 9:50 PM
$VTGN 6-17-26!
0 · Reply
LDCap
LDCap Jun. 2 at 9:38 PM
$VTGN I was heavily invested in this before the absolute disaster that was PAL3. I think I was averaging 2.60, maybe more. Sold it on the crash at 90c. Now back again 😂
1 · Reply
To_De_Moon
To_De_Moon Jun. 2 at 9:30 PM
$VTGN this will explode up soon, last opportunity to reload!!
1 · Reply
BioBum
BioBum Jun. 2 at 9:22 PM
$VTGN readout this week or next
0 · Reply
marketCaptain
marketCaptain Jun. 2 at 9:02 PM
$VTGN Already up in the AH
0 · Reply